# A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT03743051** · PHASE3 · COMPLETED · sponsor: **Helsinn Healthcare SA** · enrollment: 318 (actual)

## Conditions studied

- Cachexia; Cancer
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Anamorelin Hydrochloride
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03743051
- **Lead sponsor:** Helsinn Healthcare SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-05
- **Primary completion:** 2023-02-11
- **Final completion:** 2023-02-11
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03743051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03743051, "A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03743051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*